DENVER — At the Association for Research in Vision and Ophthalmology meeting here, Ronald D. Frenkel, MD, discusses an analysis of vision in patients being treated for wet-AMD with ranibizumab at 2 years. He found that low-luminance visual acuity gains were greater than the gains made under normal lighting conditions.
(MedPage Today) — Limited data suggest intraocular bleeding risk is similar to other antithrombotics.
The BrightFocus Foundation awarded seven scientists with research grants to advance their work in the fields of macular degeneration and glaucoma, the foundation announced in a press release.BrightFocus President and CEO Stacy Haller said in the release, “We are proud to honor and support these researchers as they strive for new treatments and cures for vision diseases.” The recognized seven are among 29 researchers receiving $5.1 million in vision grants from BrightFocus.
ALAMEDA, Calif.–(BUSINESS WIRE)–InSite Vision Incorporated (OTCBB:INSV) announced that it will report financial results for the first quarter ended March 31, 2015 on Thursday, May 14, 2015.
IRVINE, Calif. & BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Richard Croarkin has been elected to the Company’s Board of Directors, effective May 7, 2015. Mr. Croarkin brings extensive financial experience acro
Humira met its primary endpoint of extending the time to treatment failure in patients with noninfectious uveitis who still experienced intraocular inflammation despite systemic corticosteroid therapy, manufacturer AbbVie announced in a press release a…